COVID levels rising in much of U.S., with highest in West, CDC says
In an update shared Friday, official data showed wastewater activity for COVID-19 is now at a "moderate" level nationwide, up from "low" the previous week.
Wastewater levels for the virus are currently the highest in the Western U.S., the data also showed. States in this region showing high levels include: Alaska, California, Colorado, Nevada and Utah.
"Wastewater monitoring can detect viruses spreading from one person to another within a community earlier than clinical testing and before people who are sick go to their doctor or hospital," the CDC notes. "If you see increased wastewater viral activity levels, it might indicate that there is a higher risk of infection."
Other metrics are also showing increases in the illness. As of Tuesday, the CDC estimates COVID-19 infections are growing or likely growing in 45 states, which is up from 40 states last week.
And although the weekly percentage of emergency room visits for COVID-19 is overall low — compared to the week before, ER visits for the infection have also risen from last week.
As the nation saw the number of COVID cases increase last month, CBS News chief medical correspondent Dr. Jon LaPook told "CBS Mornings" that this is typical of what we've come to understand about summer spikes.
"We now know that there's a winter spike and then there's a summer spike," he said at the time. "And every year, the number of deaths, the number of hospitalizations, is gradually going down each season. So that's the good news."
But, people shouldn't ignore the increases, he said, adding if it strikes — especially those vulnerable like the elderly, young people and those immunocompromised — as they can still get really sick.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
Wound Care Market worth US$30.48 billion by 2030 with 6.5% CAGR
DELRAY BEACH, Fla., Aug. 11, 2025 /PRNewswire/ -- The global Wound Care Market, valued at US$20.97 billion in 2024 stood at US$22.22 billion in 2025 and is projected to advance at a resilient CAGR of 6.5% from 2025 to 2030, culminating in a forecasted valuation of US$30.48 billion by the end of the period. The wound care market is primarily driven by the increasing cases of traumatic and burn injuries, growing prevalence of chronic diseases, and rising geriatric population. These factors have contributed to the higher demand for effective wound management solutions. Additionally, supportive government initiatives and reimbursement frameworks further bolster market growth. However, the high cost of advanced wound care products and associated risks may limit their widespread adoption. On the other hand, emerging economies offer significant growth opportunities, supported by ongoing technological advancements in wound care. Despite this, market expansion is challenged by a shortage of trained healthcare professionals and limited awareness in underdeveloped regions. Download PDF Brochure: Browse in-depth TOC on "Wound Care Market" 589 - Tables 61 - Figures 457 - Pages By wound type, the wound care market is divided into two main segments based on wound type: chronic wounds and acute wounds. Chronic wounds are further divided into diabetic foot ulcers, pressure ulcers, venous leg ulcers, and other chronic wounds. The chronic wounds segment of the wound care held the largest market share in 2024. Chronic wounds are more prominent due to their high incidence and the need for quick, targeted treatment. These types of wounds require wound care products to prevent infection and support faster and efficient healing. Additionally, increasing surgical procedures and accidental injuries worldwide continue to drive demand in this segment. By end users, the wound care market is divided into hospitals & clinics, home care settings, long-term care facilities, and other end users. Among these end users, the hospitals & clinics segment held the largest market share in 2024 for wound care. Hospitals & clinics are further divided into inpatient settings and outpatient settings. Hospitals & clinics lead the market due to their ready access to advanced technologies and trained medical staff. These settings handle a larger number of complex wound patients, requiring specialized care. Their ability to provide immediate and continuous treatment further supports their dominant role in the market. By geography, the wound care market is segmented into five major segments, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America had the largest market share in the wound care market in 2024. This is due to the increasing prevalence of diabetes, which leads to diabetic foot ulcers in the geriatric population. Additionally, the huge presence of wound care manufacturing companies in the region is increasing the market growth. The US has also observed a rise in obesity and road accidents, which has boosted the wound care market in North America. Request Sample Pages : Prominent players in the wound care market include Solventum (US), Johnson & Johnson Services, Inc. (US), Smith+ Nephew (UK), Convatec Group PLC (UK), Coloplast Group (Denmark), Cardinal Health (US), Mölnlycke AB (Sweden), Integra LifeSciences Corporation (US), PAUL HARTMANN AG (Germany), SE (Germany), Organogenesis Inc. (US), MIMEDX Group, Inc. (US), Essity Aktlebolag (Sweden), Avery Dennison Corporation (US), Mativ Holdings, Inc. (US), Owens & Minor (US), Zimmer Biomet (US), Bioventus (US), Medtronic (Ireland), and Baxter (US). Solventum (US): Following its spinoff from 3M in April 2024, Solventum embarked on a new journey as an independent company. While it previously benefited from 3M's resources and brand recognition, Solventum is now focused on establishing its own identity. The company develops, manufactures, and markets a wide range of products aimed at meeting the needs of both patients and healthcare providers. Its operations are structured across four key business segments: MedSurg, Dental Solutions, Health Information Systems, and Purification & Filtration. To drive growth, Solventum is prioritizing innovation and strategic expansion. The company enhances its competitive position by combining material science with digital technologies, delivering improved clinical and economic outcomes for healthcare systems. Johnson & Johnson Services, Inc. (US) Johnson & Johnson, a global healthcare powerhouse, maintains a leading position in the wound care market through its surgical technologies arm, Ethicon. The company provides an extensive portfolio of advanced wound closure solutions, including sutures, staplers, and sealants that are widely utilized in surgical and acute care environments. Leveraging decades of clinical expertise, strong evidence-based outcomes, and a commitment to continuous innovation, the company effectively addresses a broad spectrum of surgical wound care needs. Supported by Johnson & Johnson's expansive global manufacturing and distribution infrastructure, Ethicon strengthens the company's ability to deliver high-quality, scalable, and dependable wound care solutions worldwide. Smith+Nephew (UK) The company offers a wide portfolio of wound care products, including advanced dressings and NPWT devices. It maintains a strong global market presence, largely due to its efficient distribution network. Its worldwide reach and the essential nature of its products play a key role in expanding healthcare access across both developed and emerging markets. In recent years, the company has increased its focus on research and development to create more effective and differentiated products. It invested USD 289.0 million in 2024, USD 339.0 million in 2023, and USD 345.0 million in 2022 in R&D activities. This consistent commitment to innovation has helped establish the company as a recognized name in the wound care industry. For more information, Inquire Now! Related Reports: Advanced Wound Care Market Traditional Wound Care Market Animal Wound Care Market Wound Care Biologics Market Burn Care Market Get access to the latest updates on Wound Care Companies and Wound Care Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets Sign in to access your portfolio
Yahoo
2 minutes ago
- Yahoo
Ousted FDA vaccine chief Vinay Prasad is returning to the agency
WASHINGTON (AP) — A Food and Drug Administration official is getting his job back as the agency's top vaccine regulator, less than two weeks after he was pressured to step down at the urging of biotech executives, patient groups and conservative allies of President Donald Trump. Dr. Vinay Prasad is resuming leadership of the FDA center that regulates vaccines and biotech therapies, a spokesperson for the Department of Health and Human Services said in a statement Monday. Prasad left the agency late last month after drawing ire of right-wing activists, including Laura Loomer, because of his past statements criticizing Trump. A longtime a critic of FDA's standards for approving medicines, Prasad briefly ordered the maker of a gene therapy for Duchenne's muscular dystrophy to halt shipments after two patient deaths. But that action triggered pushback from the families of boys with the fatal condition and libertarian supporters of increased access to experimental medicines. Prasad's decision to pause the therapy was criticized by The Wall Street Journal editorial board, former Republican Sen. Rick Santorum and others. The FDA swiftly reversed its decision suspending the therapy's use. Loomer posted online that Prasad was 'a progressive leftist saboteur,' noting his history of praising liberal independent Sen. Bernie Sanders. But Prasad has had the backing of FDA Commissioner Marty Makary and health secretary Robert F. Kennedy Jr., who have both called for scrutinizing the use of COVID-19 vaccines. Under Prasad, the FDA restricted the approval of two new COVID-19 shots from vaccine makers Novavax and Moderna and set stricter testing requirements for future approvals. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content. The Associated Press Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 minutes ago
- Yahoo
‘Remarkable' pancreatic cancer jab offers longer survival hope for patients
Pancreatic cancer patients have been given fresh hope after a new vaccine appeared to slow disease progression and increase survival. Researchers described the findings as 'remarkable' and have already started testing the efficacy of the jab among a larger group of pancreatic and bowel cancer patients. Pancreatic cancer has some of the poorest cancer survival rates because it is often not detected until it is advanced. Many patients see their cancer unremitting, even after undergoing traditional treatments including chemotherapy and radiotherapy. Now a new vaccine has been developed to help harness the body's immune system to find and attack cancer cells. The jab has shown promise in an early trial. Pancreatic and bowel cancers frequently carry a mutation in a gene called KRAS. This mutation plays a key role in tumour growth and scientists developed the jab to recognise and attack KRAS-mutant cancer cells. The jab is a new type of immunotherapy vaccine designed specifically to improve vaccine delivery to the lymph nodes, which act as filters for foreign substances in the body including cancer cells and infections. The phase 1 trial involved 20 patients with pancreatic cancer and five patients with bowel cancer. After an average follow-up time of almost 20 months, 68% of patients had developed strong immune responses specific to mutant KRAS tumour proteins. Though the study showed that some responded more favourably compared to others. Patients who had the strongest immune responses lived longer and stayed cancer free for longer than those with weaker responses. On average pancreatic cancer patients survived about two years and five months after receiving the vaccine, according to the study, which has been published in the journal Nature Medicine. At present, just three in 10 people diagnosed with the condition survive for a year. Meanwhile the average time before the disease returned, also known as recurrence free survival, was more than 15 months. While some cancer jabs are personalised to each patient, this jab, ELI-002 2P, has a single version which can be given to all patients. This 'off-the-shelf' version means that it can be manufactured in bulk and given more rapidly. Study lead Dr Zev Wainberg, from the University of California, Los Angeles, in the US, told the PA news agency: 'Pancreas cancer (patients) even after all standard treatments, such as chemotherapy and radiation, still have very high risks of the cancer coming back. 'Our results show in the group of patients who had profound immune responses (17/25 68%) achieved had longer survival than we have expected in this cancer, quite a remarkable finding to occur in a phase 1 trial.' He added: 'This is the first trial using a new platform, called AMP technology. 'The technology was invented by a material scientist engineer and immunology, Darrel Irvine, in his lab at MIT, and the platform was designed to improve vaccine delivery to lymph nodes which play a special role in the immune response.' Asked about next steps, he added: 'We launched a randomised phase 2 based on the initial results from the Amplify-201 study in January 2024. 'The accrual of the 144 patients participating was very rapid for this trial, which completed enrolment last December, and we are looking forward to the results as follow up continues.' Dr Chris Macdonald, head of research at the charity Pancreatic Cancer UK, said: 'Immunotherapy, and in particular cancer vaccines, hold so much opportunity in the treatment of pancreatic cancer, but so far the opportunity has not been realised. 'However in recent years, this is changing. This study is the latest in a rapidly progressing field. 'This early-stage study takes an important step, showing the effectiveness of an 'off-the-shelf' cancer vaccine, potentially breaking a reliance on having to generate a vaccine specifically for every individual patient. 'This approach saves time and is less costly and resource heavy, meaning more people could potentially benefit. 'The future is bright and if the momentum in this field continues to grow, more people could have the opportunity to benefit from immunotherapy, helping them to live better for longer.' Dr Dani Edmunds, research information manager at Cancer Research UK, added: 'Although we've helped to double cancer survival in the UK in the past 50 years, progress has not been the same for pancreatic cancer which remains hard to treat. 'Therefore, it's promising to see that vaccines could help people with pancreatic and bowel cancer live cancer-free for longer. 'The results suggest that the vaccine can boost the immune system against cancer in some people following standard treatment. 'These people survived and stayed free from disease for longer than people who didn't get as strong an immune boost following vaccination. 'Larger controlled trials are needed to confirm these initial findings about the benefits of the vaccine. 'More research is needed to understand why some people benefit from the vaccine while others don't so that we can make sure we're beating cancer for everyone.'
